Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Rating of “Hold” from Brokerages

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have received an average rating of “Hold” from the twenty brokerages that are presently covering the firm, Marketbeat.com reports. Twelve analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $82.06.

A number of analysts have recently commented on the company. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Truist Financial boosted their target price on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 15th. Royal Bank of Canada lifted their price target on Gilead Sciences from $72.00 to $74.00 and gave the stock a “sector perform” rating in a research note on Wednesday, September 4th. Finally, BMO Capital Markets upped their target price on Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, August 9th.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now owns 114,979 shares in the company, valued at approximately $8,506,146.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently modified their holdings of the company. Gilbert & Cook Inc. increased its stake in shares of Gilead Sciences by 5.3% during the fourth quarter. Gilbert & Cook Inc. now owns 6,791 shares of the biopharmaceutical company’s stock valued at $550,000 after acquiring an additional 344 shares during the period. Aveo Capital Partners LLC grew its position in Gilead Sciences by 8.6% during the 4th quarter. Aveo Capital Partners LLC now owns 5,473 shares of the biopharmaceutical company’s stock worth $443,000 after purchasing an additional 435 shares in the last quarter. J. W. Coons Advisors LLC raised its position in Gilead Sciences by 2.8% during the fourth quarter. J. W. Coons Advisors LLC now owns 11,130 shares of the biopharmaceutical company’s stock valued at $902,000 after buying an additional 300 shares during the period. Evoke Wealth LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $204,000. Finally, Rathbones Group PLC boosted its stake in shares of Gilead Sciences by 3.7% during the 4th quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company’s stock valued at $339,000 after buying an additional 150 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $83.84 on Tuesday. The firm has a 50 day moving average of $78.28 and a two-hundred day moving average of $71.60. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $87.86. The stock has a market capitalization of $104.45 billion, a PE ratio of 232.89, a P/E/G ratio of 2.91 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The business had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. On average, research analysts predict that Gilead Sciences will post 3.78 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.67%. The ex-dividend date was Friday, September 13th. Gilead Sciences’s payout ratio is currently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.